HORMONAL CONTRACEPTION IN YOUNG WOMEN: PREFERENCES, EXPECTATIONS, ADHERENCE
- Authors: Dikke G.B.1
-
Affiliations:
- Peoples' Friendship University of Russia, Ministry of Education of Russia
- Issue: No 11 (2015)
- Pages: 28-35
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247513
- ID: 247513
Cite item
Abstract
Objective. To define contraceptive methods preferred by young women, their expectations of chosen hormonal means to prevent an unwanted pregnancy, and a way to enhance their adherence. Subjects and methods. The results of a sociological survey of 1007young women, conducted in 2012, were analyzed. A structured interview, a method to retrieve information from a questionnaire containing open- questions, was applied; 402 Moscow students were anonymously interviewed. Results. The survey demonstrated the current characteristics of marriage, reproductive, and contraceptive behavior in 20-24-year-old women: a decline in the number of registered marriages (29.3%), stabilization of birth rates at a level of 90%o, a 26% reduction in abortion rates in the past 15 years; condom preferences (59%), coitus interruptus (26%), and combined oral contraceptives (COCs) (33%) with a low adherence to the latter. The main expectations of the women in choosing a hormonal contraceptive were its high efficacy, minimum side effects, convenience and easiness to use, and good menstrual cycle control. The above parameters were used to compare a number of COCs. The latter in a 24/4 regimen containing 20 fig of ethinylestradiol and 3 fig of drospirenone were noted to have advantages in reducing the incidence of adverse reactions and in having additional non-contraceptive benefits that were of importance for the young women to choose a contraceptive. Conclusion. Reliable contraceptives containing minimal hormones, which guarantee minimum side effects and high menstrual cycle control, may become an effective alternative for young women, by enhancing their adherence.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Galina Borisovna Dikke
Peoples' Friendship University of Russia, Ministry of Education of Russia
Email: galadikke@yandex.ru
Honoured Science and Education, MD, professor of obstetrics, gynecology and reproductive medicine faculty of continuing medical education Moscow 117198, Miklukho-Maklaya str. 8, Russia
References
- Дакке Г.Б., Ерофеева Л.В. Особенности репродуктивного поведения молодежи. Акушерство и гинекология. 2013; 12: 96-101. [Dikke G.B., Erofeeva L.V. Featuresofreproductive behavior ofyoung people. Akusherstvo і ginekologiya/Obstetrics and gynecology. 2013; 12: 96-101. (in Russian)]
- Уварова E.B. Комбинированная гормональная контрацепция у сексуально активных подростков и молодежи. Русский медицинский журнал. 2008; 16(19): 1232-5. [Uvarova E.V. Combined hormonal contraception in sexually active adolescents and young adults. Russkiy meditsinskiy zhumal. 2008; 16(19): 1232-5. (in Russian)]
- Захаров С. Брачность в России: история и современность. Электронная версия бюллетеня «Население и общество» Демоскоп Weekly. 2006; № 261-262. Available at: http://demoscope.ru/ [Zaharov S. Marriages in Russia: history and modernity. The electronic version of the newsletter “Citizens and Society” Demoscope Weekly. 2006; № 261-262. Available at: http://demoscope.ru/ (in Russian)]
- Федеральная служба государственной статистики. Женщины и мужчины России. Статистический сборник. 2014. Электронная версия. Available at: http://www.gks.ru [Federal State Statistics Service. Women and men of Russia. Statistical Yearbook. 2014. An electronic version. Available at: http://www.gks.ru (in Russian)]
- Бирюкова C.C., Тындик А.О. Регистрация брака и рождение ребенка в биографии россиян: анализ данных текущей статистики. Демографическое обозрение. 2014; 1(3): 33-64.
- Щербакова E. Рост числа родившихся продолжает замедляться, число абортов сокращается. Электронная версия бюллетеня «Население и общество» Демоскоп Weekly. 2014; №587-588. Available at: http://www. demoscope.ru
- Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. М.; 2013. 200с.
- Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug Investig. 2010; 30(11): 749-63.
- Eeming K.L., Sokoloff A., Raine T.R. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception. 2010; 82(2): 178-82.
- Winner B., Peipert J.F., Zhao Q., Bucket C., Madden T. Allsworth J.E., Secura G.M. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012; 366(21): 1998-2007.
- Egarter C., Frey Tirri B., Bitter J., Kaminskyy V, Oddens B.J., Prilepskaya V etal. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health. 2013; 13: 9. Available at: http:// www. ncbi. nlm. nih.gov/
- Ersek J.L., Brunner Huber L.R., Thompson M.E., Warren-Findlow J. Satisfaction and discontinuation of contraception by contraceptive method among university women. Matem. Child Health J. 2011; 15(4): 497-506.
- Moreau C., Geland K, Trussed J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76(4): 267-72.
- Алесина И.Л. Консультирование женщин как важный инструмент при индивидуальном подборе метода контрацепции. Акушерство и гинекология. 2011; 6: 120-4.
- Hatcher R.A., Rinehart W., Blackburn R.r GellerJ.S., Shelton J.D. The essentials of contraceptive technology. Baltimore: The Johns Hopkins Bloomberg School of Public Health, Population Information Program; 2003. 355p.
- Halpem V, Lopez L.M., Grimes D.A., Stockton L.L., Gallo M.F Strategies to improve adherence and acceptability of hormonal methods of contraception. (Review). Cochrane Database Syst. Rev. 2013; (10): CD004317. Available at: http://onlinelibrary.wiley.com/
- Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., Schulz KF 20 pg versus >20 pg estrogen combined oral contraceptives for contraception. (Review). Cochrane Database Syst. Rev. 2013; (8): CD003989. Available at: http:// onlinelibrary.wiley.com /
- Endrikat J., Parke S., Trummer D., Schmidt W., Duijkers I., Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008; 78(3): 218-25.
- Ahrendt H.J., Makalova D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven- cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44.
- Oelkers W., Foidart J.M., Dombrovicz N. Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab. 1995; 80(6): 1816-21.
- Losert W., Casals-Stenzel J., Base M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985; 35(2): 459-71.
- Nakajima S.T., Archer D.E, Ellman II. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 pg (Loestrin 24 Fe). Contraception. 2007; 75(1): 16-22.
- Карахалис Л.Ю., Жигаленко A.P, Стебло Е.И. Контрацептивные и неконтрацептивные эффекты дроспиренона. Репродуктивное здоровье детей и подростков. 2015; 2: 73-7. [Karahalis L.Yu., Zhigalenko A.R., StebloE.I. Contraceptive and non-contraceptive effects of drospirenone. Reproduktivnoezdorovedetey і podrostkov. 2015; 2:73-7. (in Russian)]
- Willis S.A., Kuehl T.J., Spikerman A.M., Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006; 74(2): 100-3.
- Caiyan W., Wen D., Qinping L., Huan S., Ziyan H., Liangdan I et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 pg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(5): 355-9.
- Fu Y, Mi W., Li L., Zhang H, Wang J., Cheng W et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 pg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(7): 506-9.
- Mansour D., Verhoeven C., Sommer W., Weisberg E., Taneepanichskul S., Melis G.B. et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17[3-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care. 2011; 16(6): 430-43.
- Прилепская B.H., Новикова Е.П. Дроспиренон-содержащие контрацептивные средства - возможности расширяются. Фарматека. 2012; 12: 49-52.
- ГеворкянМ.А.,МанухинИ.Б., ТихомировА.Л., Кузнецова F.M Опыт применения дроспиренон-содержащего гормонального контрацептива. Русский медицинский журнал. 2011; 19(1): 24-33.
- Тихомиров А.Л. Комбинированная по составу и востребованности гормональная контрацепция. Русский медицинский журнал. 2014; 22(1): 38-40.
- Gallo M.F, Lopez L.M., Grimes D.A., Carayon F, Schulz K.F, Helmerhorst F.M. Combination contraceptives: effects on weight. (Review). Cochrane Database Syst. Rev. 2014; (1): CD003987. Available at: http://onlinelibrary.wiley.com/
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62(1): 29-38.
- Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care. 2000; 5(2): 124-34.
- Lawrie T.A., Helmerhorst F.M., Maitra N.K, Kulier R., Bloemenkamp K, Giilmezoglu A.M. Types of progestogens in combined oral contraception: effectiveness and side-effects. (Review). Cochrane Database Syst. Rev. 2011; (5): CD004861. Available at: http://onlinelibrary.wiley.com/
- Nappi R.E., Albani F, Tonani S., Santamaria V, Pisani C., Terreno E. et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. 2009; 24(2): 71-5.
- Apter D., Borsos A., Baumgartner W., Melis G.B., Vexiau-Robert D., Colligs-Hakert A. et a/. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care. 2003; 8(1): 37-51.
- Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low- dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin. Drug Invest. 2009; 29(2): 73-8.
- Gruber D.M., Huber J.C., Melis G.B., Stagg C., Parke S., Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 pg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 pg and desogestrel 150 mug. Treat. Endocrinol. 2006; 5(2): 115-21.
- Marr J., Heinemann K, Kunz M., Rapkin A. Ethinylestradiol 20 pg/ drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int. J. Gynaecol. Obstet. 2011; 113(2): 103-7.
- Басова O.H., Волков В.Г. Сравнительная характеристика эффективности комбинированных оральных контрацептивов в терапии ПМС: рандомизированное контролируемое исследование. Проблемы репродукции. 2011; 4: 27-31.
- Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 2008; 53(9): 729-41.
- Прилепская B.H., Межевитинова E.A., Сасунова P.A., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012; 2: 81-5.
- Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. (Review). Cochrane Database Syst. Rev. 2012; (2): CD006586. Available at: http://onlineli- brary.wiley.com/
- Wong C.L., Farquhar C., Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. (Review). Cochrane Database Syst. Rev. 2009; (4): CD002120. Available at: http://onlinelibrary.wiley.com/
- Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. (Review). Cochrane Database Syst. Rev. 2012; (7): CD004425. Available at: http://onlinelibrary.wiley.com/
- van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002; 69(4, Suppl.): 2-15.
- Maloney J.M., Dietze P. Jr., Watson D., Niknian M., Lee-Rugh S., Sampson-Landers C., Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet. Gynecol. 2008; 112(4): 773-81.
- Koltun W, Lucky A. W., Thiboutot D., Niknian M., Sampson-Landers C., KornerP., MarrJ. Efficacy and safety of 3 mg drospirenone/20 mcgethi- nylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008; 77(4): 249-56.
- Артымук H.B., Букреева Е.Л. Сравнительная оценка влияния сочетания 3 мг дроспиренона и 20 или 30 мкг этинилэстрадиола на состояние кожи и антропометрические показатели. Фарматека. 2015; 3: 31-3.
Supplementary files
![](/img/style/loading.gif)